Sort
10,766 grants matching “checkpoint inhibitor”
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
$394,250Dario C. Altieri · Wistar Institute · R01 · FY2016 · CA
Covalent Protein Binders for Cancer Research and Therapy
$394,164Lei Wang · University Of California, San Francisco · R01 · FY2022 · CA
Biomaterials-based Germinal Center Niches for Understanding the B Cell Maturation and B cell receptor signaling
$394,088Ankur Singh · Cornell University · R01 · FY2019 · AI
Regulation and Function of the Matricellular Protein CCN1 in Ischemic Retinopathy
$393,973Brahim Chaqour · Suny Downstate Medical Center · R01 · FY2017 · EY
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer
$393,940Rugang Zhang · Wistar Institute · R01 · FY2019 · CA
The integrated stress response and the microenvironment in melanoma progression
$393,894Constantinos Koumenis · University Of Pennsylvania · R01 · FY2024 · CA
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
$393,853Constantine S. Mitsiades · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2022 · OD
Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance
$393,750Roger S Lo · University Of California Los Angeles · R01 · FY2025 · CA
Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance
$393,750Roger S Lo · University Of California Los Angeles · R01 · FY2024 · CA
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2020 · OD
Immune Activating CAR-Modified Antigen Presenting Cells
$393,750Carl Deselm · Washington University · DP5 · FY2021 · OD
Mechanisms of Nucleic Acid Enzymes - Pol Beta, HIV-1 Reverse Transcriptase and Mammalian Base Repair Enzymes
$393,661Samuel H Wilson · National Institute Of Environmental Health Sciences · ZIA · FY2019 · ES
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
$393,625Calvin J Kuo · Stanford University · R01 · FY2021 · DK
Implications of the ATR Checkpoint Kinase in Radiation and Targeted Therapies
$393,623Lee Zou · Massachusetts General Hospital · R01 · FY2016 · CA
PPARy, TLR Signaling and Atherosclerosis
$393,534Christopher K Glass · University Of California, San Diego · P01 · FY2011 · HL
Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damage
$393,522Karen McLean · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
$393,500Calvin J Kuo · Stanford University · R01 · FY2023 · DK
Intestinal organoid modeling of SARS-CoV-2-stimulated innate and adaptive immunity
$393,500Calvin J Kuo · Stanford University · R01 · FY2022 · DK
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2018 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade
$393,450Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2017 · CA
Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
$393,401Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R21 · FY2024 · CA
The Inhibition of HNSCC Growth and Metastasis by Targeting KDM4A
$393,397Cun-Yu Wang · University Of California Los Angeles · R01 · FY2022 · DE